Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Identification of Carotid Plague Vulnerability by Contrast Enhanced Ultrasound: Correlation With Plague Histopathology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02820207
Recruitment Status : Completed
First Posted : June 30, 2016
Last Update Posted : July 24, 2020
Sponsor:
Information provided by (Responsible Party):
Zhao Keqiang, Beijing Tsinghua Chang Gung Hospital

Tracking Information
First Submitted Date June 20, 2016
First Posted Date June 30, 2016
Last Update Posted Date July 24, 2020
Actual Study Start Date January 13, 2016
Actual Primary Completion Date November 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 19, 2017)
the incidence of ischemia shock [ Time Frame: within 30 days after operations ]
The incidence of ischemic stroke was defined as the number of cases of postoperative cerebral infarction divided by the total number of cases
Original Primary Outcome Measures
 (submitted: June 29, 2016)
the incidence of ischemia shock [ Time Frame: within 30 days after operations ]
Change History
Current Secondary Outcome Measures
 (submitted: July 19, 2017)
  • the incidence of restenosis [ Time Frame: 6 months after operations ]
    the loss of lumen of carotid beyond 70% is defined as restenosis
  • the incidence of all-cause mortality [ Time Frame: within 30 days after operations ]
    All-cause mortality includes all causes of death, such as MI, heart failure, stroke, bleeding et al.
Original Secondary Outcome Measures
 (submitted: June 29, 2016)
  • the incidence of restenosis [ Time Frame: 6 months after operations ]
  • the incidence of all-cause mortality [ Time Frame: within 30 days after operations ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Identification of Carotid Plague Vulnerability by Contrast Enhanced Ultrasound: Correlation With Plague Histopathology
Official Title Vascular Surgery Department of Beijing Tsinghua Chang Gung Hospital
Brief Summary

OBJECTIVE/BACKGROUND: Intraplaque neovascularization is one of the most important risk factors for unstable carotid plaque. This study was designed to evaluate whether carotid intraplaque neovascularization (IPN) can be accurately assessed by contrast enhanced ultrasound (CEUS).

METHODS: Preoperative CEUS analysis of 50 carotid artery stenosis patients would be compared to histopathology performed on their plaques excised by carotid endarterectomy (CEA) with CD34 and MMP9 staining.

Detailed Description
  1. To enroll 50 cases of patients suffering from carotid artery stenosis continuously, the investigators perform contrast enhanced ultrasound on patients for identifying the vulnerable plagues and taking high resolution MR inspection to analysis those plagues at the same time.
  2. All patients undergo carotid endarterectomy. The vulnerable ingredients of carotid plaques such as intraplaque neovascularization and bleeding are identified by pathological examination and immunohistochemical staining.
  3. To evaluate the accuracy of CEUS for identifying carotid vulnerable plague compared with high resolution MR.
  4. The investigators divide patients into the stable group and the vulnerable group based on the results of CEUS inspection. To analysis the incidence of postoperative complications such as stroke and mortality within 30 days and to compare the differences between the two groups.
Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 6 Months
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population the patients suffering from carotid artery stenosis
Condition
  • Carotid Artery Plaque
  • Ultrasonic Diagnosis
Intervention Not Provided
Study Groups/Cohorts Vulnerable plague
The patients suffering from carotid artery stenosis were identified as the vulnerable plague group by Contrast Enhanced Ultrasound whose plagues were found intraplaque neovascularization
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: June 29, 2016)
50
Original Estimated Enrollment Same as current
Actual Study Completion Date June 30, 2020
Actual Primary Completion Date November 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • The patients with ischemic symptom whose carotid stenosis were more than 50%
  • The patients without ischemic symptom whose carotid stenosis were more than 70%

Exclusion Criteria:

  • Confirmed with severe intracranial vascular lesions
  • Suffering from the large area cerebral infarction or critical stroke sequela
  • Restenosis after CEA or CAS
  • Suffering from severe coronary heart disease, respiratory failure,the hypertension difficult to controled
  • Patients with malignant tumor or expected life < 2 years
Sex/Gender
Sexes Eligible for Study: All
Ages 50 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries China
Removed Location Countries  
 
Administrative Information
NCT Number NCT02820207
Other Study ID Numbers (2016)003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Zhao Keqiang, Beijing Tsinghua Chang Gung Hospital
Study Sponsor Beijing Tsinghua Chang Gung Hospital
Collaborators Not Provided
Investigators
Study Director: sifan Yang, M.D. Beijing Tsinghua Chang Gung Hospital
PRS Account Beijing Tsinghua Chang Gung Hospital
Verification Date July 2020